OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Neurology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza	462
Burden of Neurological Disorders Across the US From 1990-2017	317
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease	304
Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome	297
Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children	297
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum	269
Association of Delirium With Long-term Cognitive Decline	265
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease	243
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis	234
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease	204
Global Prevalence and Incidence of Tinnitus	183
Global Prevalence of Young-Onset Dementia	179
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease	175
Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion	170
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy	170
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease	169
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel	167
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US	166
Assessment of ¹⁸F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy	163
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex	162
Clinical Presentation, Investigation Findings, and Treatment Outcomes of Spontaneous Intracranial Hypotension Syndrome	160
One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China	154
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study	150
Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing	148
Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients	145

Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy	140
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab	139
Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study	138
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes	131
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity	130
Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging	129
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease	124
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability	124
Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes	123
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum	119
Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis	117
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis	116
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis	114
Autoimmune Encephalitis Misdiagnosis in Adults	114
Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets	112
Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died	111
Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US	109
Seizure Cycles in Focal Epilepsy	107
Assessment of Emergency Department and Inpatient Use and Costs in Adult and Pediatric Functional Neurological Disorders	106
Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis	104
Thrombectomy for Primary Distal Posterior Cerebral Artery Occlusion Stroke	101
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers	99
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease	99
Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension	99
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis	98
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis	95
Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease	95
Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease	94
Association of NO₂ and Other Air Pollution Exposures With the Risk of Parkinson Disease	93
Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia	92
Recovery of Consciousness and Functional Outcome in Moderate and Severe Traumatic Brain Injury	92
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography	90
Association of Field Position and Career Length With Risk of Neurodegenerative Disease in Male Former Professional Soccer Players	89
Prevalence of High-risk Plaques and Risk of Stroke in Patients With Asymptomatic Carotid Stenosis	88
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease	87
Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US	87
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis	86
Prediction of Early Neurological Deterioration in Individuals With Minor Stroke and Large Vessel Occlusion Intended for Intravenous Thrombolysis Alone	86
Trends in Relative Incidence and Prevalence of Dementia Across Non-Hispanic Black and White Individuals in the United States, 2000-2016	85
Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California	85
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease	83
Association of Daily Step Count and Intensity With Incident Dementia in 78 430 Adults Living in the UK	83
Encephalitis Induced by Immune Checkpoint Inhibitors	80
Direct to Angiography Suite Without Stopping for Computed Tomography Imaging for Patients With Acute Stroke	79
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis	78
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology	75
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease	75
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis	74
Comparison of Prehospital Scales for Predicting Large Anterior Vessel Occlusion in the Ambulance Setting	74
Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort Study	72

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis	72
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis	72
Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy	71
Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab	71
Association of NOTCH2NLC Repeat Expansions With Parkinson Disease	71
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes	70
Association of Hearing Aids and Cochlear Implants With Cognitive Decline and Dementia	69
Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease	69
What the Aducanumab Approval Reveals About Alzheimer Disease Research	66
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination	66
Pathological Computed Tomography Features Associated With Adverse Outcomes After Mild Traumatic Brain Injury	66
Surgical Decompression for Space-Occupying Hemispheric Infarction	66
Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures	65
Hypoxic-Ischemic Encephalopathy Evaluated by Brain Autopsy and Neuroprognostication After Cardiac Arrest	63
Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment	63
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease	63
Research Criteria for the Behavioral Variant of Alzheimer Disease	59
Assessing Brain Capillaries in Coronavirus Disease 2019	58
Outcomes of Intensive Systolic Blood Pressure Reduction in Patients With Intracerebral Hemorrhage and Excessively High Initial Systolic Blood Pressure	57
Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention	57
Long-term Risk of Parkinson Disease Following Influenza and Other Infections	56
One-Year Outcome Trajectories and Factors Associated with Functional Recovery Among Survivors of Intracerebral and Intraventricular Hemorrhage With Initial Severe Disability	56
Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment	56
General Anesthesia vs Local Anesthesia in Microelectrode Recording–Guided Deep-Brain Stimulation for Parkinson Disease	56
Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19	55
Amyloid-Related Imaging Abnormalities and β-Amyloid–Targeting Antibodies	55
Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G–Associated Disorder	55
Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome	55
Six Action Steps to Address Global Disparities in Parkinson Disease	54
Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	53
Estimates of the Association of Dementia With US Mortality Levels Using Linked Survey and Mortality Records	53
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants	51
Association of Enzyme-Inducing Antiseizure Drug Use With Long-term Cardiovascular Disease	51
Assessment of Safety of a Fully Implanted Endovascular Brain-Computer Interface for Severe Paralysis in 4 Patients	51
Neurologic Prognostication After Cardiac Arrest Using Brain Biomarkers	51
Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis	50
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease	50
Assessment of Optimal Patient Selection for Endovascular Thrombectomy Beyond 6 Hours After Symptom Onset	50
Comparison of Mobile Stroke Unit With Usual Care for Acute Ischemic Stroke Management	49
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment	49
Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis	49
Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease	49
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US	49
Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia	49
Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis	48
Durability of Clinical and Quality-of-Life Outcomes of Closed-Loop Spinal Cord Stimulation for Chronic Back and Leg Pain	48
Helping the Public Understand Adverse Events Associated With COVID-19 Vaccinations	47
Antiseizure Medication Concentrations During Pregnancy	47
Sex-Specific Association of the X Chromosome With Cognitive Change and Tau Pathology in Aging and Alzheimer Disease	47
Risk of Rupture After Intracranial Aneurysm Growth	47
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies	46
Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis	46
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease	46
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease	46
Effectiveness of Lumbar Cerebrospinal Fluid Drain Among Patients With Aneurysmal Subarachnoid Hemorrhage	45
Sex Disparities in Enrollment in Recent Randomized Clinical Trials of Acute Stroke	45
Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy	45
Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis	45
Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease	45
Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy	45
Association Between Prehospital Tranexamic Acid Administration and Outcomes of Severe Traumatic Brain Injury	43
Reperfusion Treatment and Stroke Outcomes in Hospitals With Telestroke Capacity	43
Trends in Mortality Rates Among Medicare Enrollees With Alzheimer Disease and Related Dementias Before and During the Early Phase of the COVID-19 Pandemic	43
Prevalence of Incidentally Detected Signs of Intracranial Hypertension on Magnetic Resonance Imaging and Their Association With Papilledema	43
Association Between Alberta Stroke Program Early Computed Tomography Score and Efficacy and Safety Outcomes With Endovascular Therapy in Patients With Stroke From Large-Vessel Occlusion	43
Effect of Motor Skill Training in Functional Activities vs Strength and Flexibility Exercise on Function in People With Chronic Low Back Pain	43
A 5-Decade Analysis of Incidence Trends of Ischemic Stroke After Transient Ischemic Attack	43
Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice	42
Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome	42
Evaluation of Outcomes Among Patients With Traumatic Intracranial Hypertension Treated With Decompressive Craniectomy vs Standard Medical Care at 24 Months	42
A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage	42
Trends in Reperfusion Therapy for In-Hospital Ischemic Stroke in the Endovascular Therapy Era	40
Risk Factors and Prognosis of Early Posttraumatic Seizures in Moderate to Severe Traumatic Brain Injury	40
Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence	40
Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study	40
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios	40
Association of Endovascular Thrombectomy vs Medical Management With Functional and Safety Outcomes in Patients Treated Beyond 24 Hours of Last Known Well	40
Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE)	39
Rate of Recurrent Guillain-Barré Syndrome After mRNA COVID-19 Vaccine BNT162b2	39
Endovascular Treatment After Stroke Due to Large Vessel Occlusion for Patients Presenting Very Late From Time Last Known Well	39

Prediction of Long-term Survival After Status Epilepticus Using the ACD Score	39
Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease	38
Association Between Treatment Progression, Disease Refractoriness, and Burden of Illness Among Hospitalized Patients With Status Epilepticus	38
Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population	38
Neurologic Complications of Smallpox and Monkeypox	38
Assessment of Recurrent Stroke Risk in Patients With a Carotid Web	37
DIAPH1 Variants in Non–East Asian Patients With Sporadic Moyamoya Disease	37
Direct to Angiography vs Repeated Imaging Approaches in Transferred Patients Undergoing Endovascular Thrombectomy	37
SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort	37
Anti–SARS-CoV-2 and Autoantibody Profiles in the Cerebrospinal Fluid of 3 Teenaged Patients With COVID-19 and Subacute Neuropsychiatric Symptoms	37
Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography	37
Sexual and Gender Minority Health in Neurology	36
Optimal Intensity and Duration of Walking Rehabilitation in Patients With Chronic Stroke	36
Rates of Incidental Findings in Brain Magnetic Resonance Imaging in Children	36
Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region	36
Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy	36
Clinicopathologic Features of Oculopharyngodistal Myopathy WithLRP12CGG Repeat Expansions Compared With Other Oculopharyngodistal Myopathy Subtypes	36
Healthy Life-Year Costs of Treatment Speed From Arrival to Endovascular Thrombectomy in Patients With Ischemic Stroke	36
APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry	35
Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment	35
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease	35
Suicidality Risk of Newer Antiseizure Medications	35
US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?	34
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis	34
Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke	34
Trends in Antihypertensive Medication Use Among Individuals With a History of Stroke and Hypertension, 2005 to 2016	34
Association Between Intracerebral Hemorrhage and Subsequent Arterial Ischemic Events in Participants From 4 Population-Based Cohort Studies	34
Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy	34
Molecular Diagnostic Yield of Exome Sequencing and Chromosomal Microarray in Cerebral Palsy	34
Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source	34
Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective	33
Addition of Vision Impairment to a Life-Course Model of Potentially Modifiable Dementia Risk Factors in the US	33
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by	32
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune	31
Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis	31
Subcortical Neuronal Correlates of Sleep in Neurodegenerative Diseases	31
Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage	31
Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment	30
Association of Physical Activity, Including Amount and Maintenance, With All-Cause Mortality in Parkinson Disease	30
Diverging Temporal Trends in Stroke Incidence in Younger vs Older People	30
Risk of Suicide After Dementia Diagnosis	30
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke	30
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source	30
Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow	30
Association of Mortality and Risk of Epilepsy With Type of Acute Symptomatic Seizure After Ischemic Stroke and an Updated Prognostic Model	30
Association of APOE Genotypes and Chronic Traumatic Encephalopathy	30
Brain Aging Among Racially and Ethnically Diverse Middle-Aged and Older Adults	29
Opportunities for Prevention of Concussion and Repetitive Head Impact Exposure in College Football Players	29
General Anesthesia vs Conscious Sedation for Endovascular Treatment in Patients With Posterior Circulation Acute Ischemic Stroke	29
Mapping Lesion-Related Epilepsy to a Human Brain Network	29
Time for a New Image of Parkinson Disease	28
Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack	28
Characterizing Demographic, Racial, and Geographic Diversity in Dementia Research	28
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy	28
Agent Orange Exposure and Dementia Diagnosis in US Veterans of the Vietnam Era	28
Association Between Consumption of Ultraprocessed Foods and Cognitive Decline	28
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies	28
Long-term Outcomes in Use of Opioids, Nonpharmacologic Pain Interventions, and Total Costs of Spinal Cord Stimulators Compared With Conventional Medical Therapy for Chronic Pain	28
Association of Early-, Middle-, and Late-Life Depression With Incident Dementia in a Danish Cohort	27
Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis	27
Perils of Race-Based Norms in Cognitive Testing	27
Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries	26
Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight	26
Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy	26
Neuropathologic and Clinical Findings in Young Contact Sport Athletes Exposed to Repetitive Head Impacts	26
Association of Vascular Risk Factors and Genetic Factors With Penetrance of Variants Causing Monogenic Stroke	26
Association of Miglustat With Swallowing Outcomes in Niemann-Pick Disease, Type C1	26
Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome	25
Absent Blood Oxygen Level–Dependent Functional Magnetic Resonance Imaging Activation of the Orbitofrontal Cortex in a Patient With Persistent Cacosmia and Cacogeusia After COVID-19 Infection	25
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)	25
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease	25
Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease	24
Association of Pregnancy With the Onset of Clinically Isolated Syndrome	24
Factors Associated With Risk of Recurrent Transient Global Amnesia	24
Association Between Traumatic Brain Injury and Subsequent Cardiovascular Disease Among Post-9/11–Era Veterans	24
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin	24
Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders	24
Incidence and Natural History of Pediatric Large Vessel Occlusion Stroke	24
Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura	23
Abandoning the Proteinopathy Paradigm in Parkinson Disease	23
The Future Is P-Tau—Anticipating Direct-to-Consumer Alzheimer Disease Blood Tests	23
Cognitive Behavioral Therapy for Veterans With Comorbid Posttraumatic Headache and Posttraumatic Stress Disorder Symptoms	23
Prehospital Comprehensive Stroke Center vs Primary Stroke Center Triage in Patients With Suspected Large Vessel Occlusion Stroke	23
Outcomes After Endovascular Thrombectomy With or Without Alteplase in Routine Clinical Practice	22
Association of Neurocritical Care Services With Mortality and Functional Outcomes for Adults With Brain Injury	22
Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease	22
Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease	22
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia	22
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers	22
Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis	22
Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis	22
Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage	21
Outcomes After Endovascular Therapy With Procedural Sedation vs General Anesthesia in Patients With Acute Ischemic Stroke	21
Risk Factors for Young-Onset Dementia in the UK Biobank	21
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease	21